A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages
<p>Abstract</p> <p>Background</p> <p>The cytoprotective nature of nitric oxide (NO) led to development of NO-aspirins in the hope of overcoming the gastric side-effects of aspirin. However, the NO moiety gives these hybrids potential for actions further to their aspirin...
Main Authors: | Fox Sarah, Gasco Alberto, Fruttero Roberta, Cena Clara, Lazzarato Loretta, Sheldrake Tara A, Marcarino Paolo, Turnbull Catriona M, Megson Ian L, Rossi Adriano G |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2008-07-01
|
Series: | Journal of Inflammation |
Online Access: | http://www.journal-inflammation.com/content/5/1/12 |
Similar Items
-
Signaling pathways involved in LPS induced TNFalpha production in human adipocytes
by: Festy Franck, et al.
Published: (2010-01-01) -
Effects of serotonin on LPS- or LTA- stimulated cytokine release in monocytes and macrophages
by: Wong, Bauhinia, et al.
Published: (2014) -
Selective role of mevalonate pathway in regulating perforin but not FasL and TNFalpha release in human Natural Killer cells.
by: Alessandro Poggi, et al.
Published: (2013-01-01) -
NO/HNO Releasing Derivatives of Chlorambucil and Aspirin
by: Giridharan, Kavya Sindhu
Published: (2012) -
Studies on the Pan Coating and Controlled Release of Aspirin
by: Shiou-Ying Lai, et al.
Published: (2010)